Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Your comments will be sent to our moderator for review.
By submitting your information you agree to our Privacy and Cookie Policy.

Report comment to moderator

Required fields.


Cochrane review questions benefit of Tamiflu


'In 2009, a lack of access to available trial data hampered the efforts of the Cochrane researchers to verify the safety and effectiveness of oseltamivir and led to questions over decisions to stockpile the drug while the risks and benefits remained uncertain.' 'Inadequate reporting put most of the zanamivir studies and half of the oseltamivir studies at a high risk of selection bias. There were inadequate measures in place to protect 11 studies of oseltamivir from performance bias due to non-identical presentation of placebo. Attrition bias was high across the oseltamivir studies and there was also evidence of selective reporting for both the zanamivir and oseltamivir studies. The placebo interventions in both sets of trials may have contained active substances.' Ref: Let's hope that the success of 'Alltrials' ensures that results of every trial are published, the bad as well as the good (often selective). 'Europe votes for clinical trial transparency 2nd April 2014 It’s soon going to be the law in Europe that drug clinical trials are publicly registered and results reported.' 'No excuse not to publish: MPs tell doctors regulator 2 April 2014 MPs on the House of Commons Health Committee called on the UK doctors regulator, the General Medical Council, to make it explicit to doctors that withholding trial results is misconduct and actionable.' Ref: Cochrane signs up to AllTrials initiative to campaign for registration and reporting of all clinical trials. Ref: Let's hope that in future we will have more informed and accurate choices based on more truthful data, on all medicines.

Posted date

10 April, 2014

Posted time

9:29 pm